The 2013-14 flu season is set to be the most closely watched in years. In February, FDA cleared the use of quadrivalent vaccines which protect against two A and two B strains. GlaxoSmithKline and AstraZeneca began gearing up, and Sanofi will now join them too.
AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.
Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."
In another early-stage bet, AstraZeneca's MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca ($AZN) reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease.
In another early-stage bet, AstraZeneca's MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease.
The Facility of the Year Awards recognizes winners from the U.S., Ireland, the U.K. and Switzerland, including three vaccine facilities.
When the AstraZeneca elevated MedImmune's Bahija Jallal to head up biologics development, it gutted the unit's commercial and manufacturing operations.
The big shakeup under way at AstraZeneca under new CEO Pascal Soriot has hit home at MedImmune. Peter Greenleaf is out as president of the Gaithersburg, MD-based biotech division and Bahija Jallal, now a member of an R&D troika on AstraZeneca's executive group in the wake of Martin Mackay's ouster, is stepping up to the top spot.
As Big Pharma looks to tap the burgeoning drug market in China, companies are realizing they can't bulldoze in with U.S.-approved drugs and expect a red carpet. Instead, firms such as Vertex and AstraZeneca's MedImmune are looking to partner up with local expertise to speed their way to capitalization.
Researchers at the University of Minnesota's Center for Infectious Disease Research and Policy claim current influenza vaccines offer less protection against the infectious disease than previously thought, and better ones are necessary.